Trinity Biotech PLC (TRIB) FinancialsTRIBTrinity Biotech PLC

Evaluating the bottom line, Trinity Biotech PLC maintains a gross margin of 35.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.47%, while the net margin is -40.52%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TRIB converts its operational activities into shareholder value.

In the context of the broader market, TRIB competes directly with industry leaders such as VVOS and CELZ. With a market capitalization of $4.94M, it holds a leading position in the sector. When comparing efficiency, TRIB's gross margin of 35.43% stands against VVOS's 47.41% and CELZ's N/A. Such benchmarking helps identify whether Trinity Biotech PLC is trading at a premium or discount relative to its financial performance.

Trinity Biotech has been experiencing substantial financial losses, with a net income of -$4.39 million in Q1 2026 and a gross margin of 35.43%. The total revenue for Q1 2026 was $10.84 million, but the company has a negative total equity of -$75.73 million, indicating significant financial distress.